Abstract:The purpose of this phase I study was to determine the potential efficacy of adenoviral-mediated suicide gene therapy in women with recurrent ovarian cancer. Fourteen patients were treated intraperitoneally with herpes simplex virus-thymidine kinase (HSV-TK)-encoding adenovirus (AdHSV-TK) in dosages ranging between 1x10(9) and 1x10(11) pfu. Beginning 2 days later, ganciclovir (GCV) was administered intravenously at a dose of 5 mg/kg bid for 14 days. Transient vector-associated fever was experienced by 4 of 14 … Show more
“…So far HSV 1 -tk/GCV gene therapy for ovarian cancer has being experimented with mostly in tumors transplanted into nude mice or syngeneic rats and made a great progress. [1][2][3][4] It is, however, important to emphasize that such an approach does not reflect the in vivo situation. DMBA-induced ovarian carcinogenesis provides a wellcontrolled experimental model of ovarian cancer.…”
Section: Discussionmentioning
confidence: 99%
“…D espite recent advances in the chemotherapy of ovarian cancer, [1][2][3][4][5] only 73% of stage III and IV patients respond to therapy and overall prognosis remains poor. Therefore, alternative approaches are pursued to improve and prolong therapeutic effects in patients with the condition.…”
Transfer of the herpes simplex virus type I-thymidine kinase gene, followed by the administration of ganciclovir (HSV 1 -tk/GCV) into ovarian cancer-derived cell line either in vitro or transplanted into nude mice has been shown to provide a potential strategy for the gene therapy of ovarian cancer. We investigated the antitumor effects of HSV 1 -tk/GCV strategy with a chemically induced rat ovarian cancer model and a tumor-selective gene delivery by a novel nonviral gene delivery system (GE7) through the ovarian artery and tail vein. We demonstrated the expression of a reporter gene, b-gal gene, as well as HSV 1 -tk gene in tumors and other organs, evaluated the overall antitumor effects after the GCV treatment and analyzed the tumor cell cycle phase distribution. Via the ovarian artery route, the expressions of b-gal and HSV 1 -tk in tumors were significantly stronger than those expressed in such organs as the hearts, livers, spleens, lungs and kidneys. However, no b-gal and HSV 1 -tk were detected in the tumor tissues when administrated via the tail vein, and little was found in other organs. The cell cycle analysis showed that the total S-phase of tumor cells in the test intra-arterial treatment group was considerably higher than that of the controls. The weight of the tumor tissues in the group treated by the intra-arterial route (4.0672.12 g) was much less than the group treated intravenously (18.2578.34 g) (Po.01). These findings indicated that the administration of GE7/HSV 1 -tk complex via the ovarian artery route could be a promising avenue of future human ovarian cancer treatment.
“…So far HSV 1 -tk/GCV gene therapy for ovarian cancer has being experimented with mostly in tumors transplanted into nude mice or syngeneic rats and made a great progress. [1][2][3][4] It is, however, important to emphasize that such an approach does not reflect the in vivo situation. DMBA-induced ovarian carcinogenesis provides a wellcontrolled experimental model of ovarian cancer.…”
Section: Discussionmentioning
confidence: 99%
“…D espite recent advances in the chemotherapy of ovarian cancer, [1][2][3][4][5] only 73% of stage III and IV patients respond to therapy and overall prognosis remains poor. Therefore, alternative approaches are pursued to improve and prolong therapeutic effects in patients with the condition.…”
Transfer of the herpes simplex virus type I-thymidine kinase gene, followed by the administration of ganciclovir (HSV 1 -tk/GCV) into ovarian cancer-derived cell line either in vitro or transplanted into nude mice has been shown to provide a potential strategy for the gene therapy of ovarian cancer. We investigated the antitumor effects of HSV 1 -tk/GCV strategy with a chemically induced rat ovarian cancer model and a tumor-selective gene delivery by a novel nonviral gene delivery system (GE7) through the ovarian artery and tail vein. We demonstrated the expression of a reporter gene, b-gal gene, as well as HSV 1 -tk gene in tumors and other organs, evaluated the overall antitumor effects after the GCV treatment and analyzed the tumor cell cycle phase distribution. Via the ovarian artery route, the expressions of b-gal and HSV 1 -tk in tumors were significantly stronger than those expressed in such organs as the hearts, livers, spleens, lungs and kidneys. However, no b-gal and HSV 1 -tk were detected in the tumor tissues when administrated via the tail vein, and little was found in other organs. The cell cycle analysis showed that the total S-phase of tumor cells in the test intra-arterial treatment group was considerably higher than that of the controls. The weight of the tumor tissues in the group treated by the intra-arterial route (4.0672.12 g) was much less than the group treated intravenously (18.2578.34 g) (Po.01). These findings indicated that the administration of GE7/HSV 1 -tk complex via the ovarian artery route could be a promising avenue of future human ovarian cancer treatment.
“…[8][9][10][11][12][13][14] There have been no reports evaluating this agent in NPC or head and neck cancer, both of which are common among Chinese people, often relapse locally and are often resistant to radiotherapy and chemotherapy. In this study, the majority of subjects had been diagnosed with NPC or head and neck cancer.…”
Section: Discussionmentioning
confidence: 99%
“…Phase I/II trials have subsequently been conducted using AdV/TK/GCV in a number of malignant tumors, including ovarian carcinoma, brain tumors, prostate cancer, hepatocellular carcinoma and so on. [9][10][11][12][13][14] All of these trials have shown that the approach is relatively safe, but efficacy has been localized to the injection site, which has limited its use. However, this treatment may be particularly suitable for some tumors that have the tendency to relapse locally, such as head and neck cancer or nasopharyngeal carcinoma (NPC).…”
In this study, we investigated the safety and efficacy in cancer patients of a single intra-tumor injection of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene (AdV/TK) followed by systemic administration of ganciclovir (GCV). In 18 patients with malignant tumors refractory to standard treatment, AdV/TK was injected on day 1 with dose escalation from 2.5 Â 10 11 to 1 Â 10 12 virus particles (VP), and GCV (5 mg kg À1 ) was delivered intravenously every 12 h from days 2 to 15. The most common treatment-related toxicities were transient fever (10/18) and local injection site reaction (10/18), and most adverse events were WHO grade I/II. Anti-adenovirus antibody levels increased continuously during treatment, but anti-HSV antibody levels remained stable. One patient had a PR at the injection site but PD was found in the primary site (lung cancer), one patient with fibrosarcoma of the neck had an MR, five patients had SD, and 10 patients had PD. In conclusion, AdV/TK followed by GCV can be administered safely to Chinese cancer patients, and achieved a local response with few environmental effects. Because the response was localized, single regional tumor relapse, especially after radiation, may be an indication for this suicide gene therapy.
“…1,2 Recently, based on the fact that many human cancers are the result of accumulated genetic lesions that culminate in a transformed malignant phenotype, 3 investigation into the potential usefulness of gene therapy for peritoneal metastases has been initiated. 4 Numerous reports have described cancer gene therapy with intraperitoneal administration of viral gene carriers, [5][6][7][8][9][10][11][12][13][14][15][16] while there are only a few reports of intraperitoneal administration of DNA-cationic liposome complexes for gene transfer into intraperitoneal disseminated tumors. [17][18][19][20][21] Among the various gene carriers, viral vectors are the most widely used because of their efficiency.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.